PharmiWeb.com - Global Pharma News & Resources
17-Aug-2021

Epigenomics AG: Execution of a Biobank Sale Agreement and Update of Guidance

Epigenomics AG / Key word(s): Strategic Company Decision/Change in Forecast
Epigenomics AG: Execution of a Biobank Sale Agreement and Update of Guidance

17-Aug-2021 / 21:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Epigenomics AG: Execution of a Biobank Sale Agreement and Update of Guidance

Berlin, Germany, August 17, 2021 - Today Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") has entered into an agreement with New Horizon Health Limited (6606.HK) on the sale of certain non-essential biological samples. Gross proceeds from the sale are USD 6.7 million from which Epigenomics receives USD 4.7 million at closing and the remainder is payable within 90 days based upon the Company providing verification of sample integrity and documentation. The Company is retaining all necessary samples for the on-going development of Epi proColon Next-Gen and other R&D activities. As a result of the sale, the Company is updating its current full year 2021 revenue and earnings guidance to approximately EUR 6.0 million of revenue and EUR -3.0 million to EUR -4.0 million of EBITDA before share-based payment expenses. Cash consumption in 2021 is expected to be between EUR 3.5 million and EUR 4.5 million.

Contact:
Company
Epigenomics AG, Geneststra├če 5, 10829 Berlin
Tel +49 (0) 30 24345 0, fax +49 (0) 30 24345 555, e-mail: contact@epigenomics.com

Investor Relations
IR.on AG, Frederic Hilke, Fabian Kirchmann, tel +49 221 9140 970, e-mail: ir@epigenomics.com

 

Further information on the aforementioned operating figures can be found at https://www.epigenomics.com/news-investors/financial-reports/.

Forward-looking statements

This publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause Epigenomics AG's actual results, financial condition and performance to be materially different from any future results, performance or achievements expressed or implied by such statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise.


17-Aug-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Epigenomics AG
Geneststra├če 5
10829 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir@epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A3H2184
WKN: A3H218
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1227182

 
End of Announcement DGAP News Service

Editor Details

Last Updated: 17-Aug-2021